Furthermore, epigenetic modification in both Keap1 and Nrf2 can also activate Nrf2 as demonstrated in malignant glioma, colon cancer, and breast cancer (Muscarella et al., 2011; Hanada et al., 2012; Barbano et al., 2013). Here, NFE2L2 is linked to malignant colon neoplasm.